title: A parallel-group comparison study of celecoxib with loxoprofen sodium in third mandibular molar extraction patients.
abstract: Non-steroidal anti-inflammatory drugs (NSAIDs) are used widely, but they may damage the upper gastrointestinal mucosa owing to their mechanism of action. Selective cyclooxygenase 2 (COX-2) inhibitors are known to have a reduced risk for such damage. In this comparative study, the efficacy and safety of the selective COX-2 inhibitor celecoxib for pain after third mandibular molar extraction were compared with those of loxoprofen sodium. This was a parallel-group comparison study; 107 patients who had undergone third mandibular molar extraction were given celecoxib and 102 were given loxoprofen. The level of pain on a visual analogue scale (VAS) 15 min and 30 min after taking the experimental drug decreased over time, with no significant difference between the two groups. The percentage of patients taking a second dose was 64.5% for celecoxib and 80.4% for loxoprofen. The time to second dose was significantly longer for celecoxib (533.5 min) than for loxoprofen (387.4 min). There was no significant difference in the patients' impression of efficacy between the two groups, with ratings of 'excellent' and 'good' for 77.4% in the loxoprofen group and 74.5% in the celecoxib group. These results demonstrate that celecoxib is of equal clinical value to loxoprofen for acute pain after third mandibular molar extraction.
authors.affiliation: Department of Oral and Maxillofacial Surgery, Faculty of Medicine, Saga University, Saga, Japan. Electronic address: yamashy2@cc.saga-u.ac.jp.
authors.forename: Y
authors.initials: Y
authors.lastname: Yamashita
authors.affiliation: Department of Oral and Maxillofacial Surgery, Faculty of Medicine, Saga University, Saga, Japan.
authors.forename: N
authors.initials: N
authors.lastname: Sano
authors.affiliation: Department of Oral and Maxillofacial Surgery, Faculty of Medicine, Saga University, Saga, Japan.
authors.forename: D
authors.initials: D
authors.lastname: Shimohira
authors.affiliation: Department of Oral and Maxillofacial Surgery, Faculty of Medicine, Saga University, Saga, Japan.
authors.forename: A
authors.initials: A
authors.lastname: Danjo
authors.affiliation: Department of Oral and Maxillofacial Surgery, Faculty of Medicine, Saga University, Saga, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Goto
mesh_terms: D000328:Adult; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D000068579:Celecoxib; D052246:Cyclooxygenase 2 Inhibitors / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008334:Mandible / Q000601:surgery*; D008875:Middle Aged; D008964:Molar, Third / Q000601:surgery*; D010147:Pain Measurement; D010149:Postoperative Pain / Q000188:drug therapy*; D010666:Phenylpropionates / Q000627:therapeutic use*; D011720:Pyrazoles / Q000627:therapeutic use*; D013449:Sulfonamides / Q000627:therapeutic use*; D011795:Surveys and Questionnaires; D014081:Tooth Extraction; D016896:Treatment Outcome
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D052246:Cyclooxygenase 2 Inhibitors; D010666:Phenylpropionates; D011720:Pyrazoles; D013449:Sulfonamides; C040656:loxoprofen; D000068579:Celecoxib
keywords: analgesic effect; celecoxib; loxoprofen sodium; non-steroidal anti-inflammatory drugs; post-exodontic pain